Cargando…

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis

OBJECTIVE: To gain insight into clinical practice regarding referral, early diagnosis and other aspects of the management of patients with dcSSc in Europe and the USA. METHODS: Semi-structured interviews were conducted with 84 rheumatologists (or internal medicine physicians) and 40 dermatologists i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Distler, Oliver, Allanore, Yannick, Denton, Christopher P, Matucci-Cerinic, Marco, Pope, Janet E, Hinzmann, Barbara, Davies, Siobhan, de Oliveira Pena, Janethe, Khanna, Dinesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913641/ https://www.ncbi.nlm.nih.gov/pubmed/29415230 http://dx.doi.org/10.1093/rheumatology/kex504

Ejemplares similares

Patient perception of disease burden in diffuse cutaneous systemic sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
por: Matteson, Eric L., et al.
Publicado: (2023)

Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort
por: Allanore, Yannick, et al.
Publicado: (2016)

Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review
por: Ross, Laura, et al.
Publicado: (2023)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis
por: Dobrota, Rucsandra, et al.
Publicado: (2016)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis
por: Fox, David A., et al.
Publicado: (2021)

Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
por: Herrick, Ariane L., et al.
Publicado: (2022)

Correction to: Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis
por: Fox, David A., et al.
Publicado: (2021)

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
por: Herrick, Ariane L, et al.
Publicado: (2017)

Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets
por: Nevskaya, Tatiana, et al.
Publicado: (2021)

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study
por: Peytrignet, Sébastien, et al.
Publicado: (2018)

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2019)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS)
por: Herrick, Ariane L, et al.
Publicado: (2020)

Interstitial pneumonia with autoimmune features: a new classification still on the move
por: Cavagna, Lorenzo, et al.
Publicado: (2018)

Systemic sclerosis in the time of COVID-19
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2022)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Primary Localized Cutaneous Nodular Amyloidosis and Limited Cutaneous Systemic Sclerosis: Additional Cases with Dermatoscopic and Histopathological Correlation of Amyloid Deposition
por: Atzori, Laura, et al.
Publicado: (2021)

IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk
por: Distler, O, et al.
Publicado: (2003)

Similarities between COVID-19 and systemic sclerosis early vasculopathy: A “viral” challenge for future research in scleroderma
por: Matucci-Cerinic, Marco, et al.
Publicado: (2021)

Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database
por: Allanore, Yannick, et al.
Publicado: (2020)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2013)

Registry Evaluation of Digital Ulcers in Systemic Sclerosis
por: Galluccio, Felice, et al.
Publicado: (2010)

Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population
por: Hachulla, Eric, et al.
Publicado: (2015)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study
por: Jaeger, Veronika K., et al.
Publicado: (2016)

A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)
por: Griffiths-Jones, Deborah J, et al.
Publicado: (2023)

Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry
por: Matucci-Cerinic, Marco, et al.
Publicado: (2016)

Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination
por: Cole, Alice, et al.
Publicado: (2022)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study
por: Herrick, Ariane L, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nsjb1j989plqb3nvv3sqknfue8